Regor Announces Promising Safety And Single Agent Efficacy Data Evaluating RGT-419B In HR+/HER2- Advanced Breast Cancer Patients Who Have Progressed On CDK4/6 Inhibitors And Endocrine Therapy

RGT-419B, a next generation CDK4 inhibitor, was safe and well tolerated in a First-in-Human Phase 1A single agent dose escalation study. Monotherapy clinical efficacy was observed in HR+/HER2- advanced breast cancer (ABC) patients who have progressed on CDK4/6 inhibitors (CDK4/6is) and…